Breaking News Instant updates and real-time market news.

TDOC

Teladoc

$55.49

-0.08 (-0.14%)

06:08
01/14/19
01/14
06:08
01/14/19
06:08

Teladoc upgraded to Outperform from Neutral at Baird

TDOC Teladoc
$55.49

-0.08 (-0.14%)

11/28/18
KEYB
11/28/18
NO CHANGE
KEYB
KeyBanc sees Amazon entry having little near-term impact on HCIT space
The announcement that Amazon.com (AMZN) is developing Software-as-a-Service analytical tools for the U.S. healthcare industry called Amazon Comprehend Medical will likely bring a "lot of noise, but little real, near-term financial impact" to the publicly traded Healthcare Technology and Services space, KeyBanc analyst Donald Hooker tells investors in a research note. He believes companies potentially most relevant to Amazon's announcement include Allscripts Healthcare Solutions (MDRX), Cerner (CERN), Evolent Health (EVH), Inovalon Holdings (INOV), IQVIA Holdings (IQV), Medidata Solutions (MDSO), PRA Health Sciences (PRAH), Premier (PINC), and Teladoc Health (TDOC). Hooker argues that any potential success by mega-tech companies, such as Amazon, to develop useful SaaS analytical tools "could actually empower traditional HCIT and biopharma outsourcing companies." Further, he sees a number of "unique barriers" for "big data" solutions in clinical decision support and population health management.
12/06/18
PIPR
12/06/18
NO CHANGE
Target $88
PIPR
Overweight
Teladoc weakness on SIRF report a buying opportunity, says Piper Jaffray
After the Southern Investigative Reporting Foundation, or SIRF, published a report including allegations of a workplace relationship between Teladoc CFO Mark Hirschhorn and an employee, Piper Jaffray analyst Sean Wieland said he believes the CFO being replaced is unlikely given the company's earlier investigation. While he believes it is important for the company to take steps to promote a fair, inclusive, and equitable workplace, Wieland noted that alleged actions of the CFO don't affect the telehealth market, nor the company's product offerings or demand for the service. Given that, and his belief that the risk of a CFO change is unlikely, he recommends buying on weakness and keeps an Overweight rating and $88 price target on Teladoc shares.
01/04/19
OPCO
01/04/19
NO CHANGE
Target $31
OPCO
Outperform
Healthcare IT pullbacks create 'great' opportunities, says Oppenheimer
Oppenheimer analyst Mohan Naidu says that recent pullbacks are creating some "great" opportunities in Healthcare IT and believes, in particular, Evolent Health (EVH), Omnicell (OMCL), Tabula Rasa HealthCare (TRHC) and Teledoc (TDOC) stand out. In a research note to investors, Naidu contends that Evolent will gain from the finalized CMS regulations and increased push to risk-based models, and says Omnicell's story is significantly de-risked with traction in XT implementations. He also adds that Tabula Rasa should deliver on multiple growth drivers brewing in 2019 including PACE. and that despite the near-term distractions, Teledoc's story remains intact with significant telehealth adoption and utilization focus.
01/08/19
PIPR
01/08/19
NO CHANGE
PIPR
Overweight
Piper survey finds 'remarkable increase' in receptivity to telemedicine
Piper Jaffray analyst Sean Wieland says his firm's third annual consumer healthcare survey reveals a "remarkable increase" in consumer receptivity to telemedicine. The likelihood of someone choosing telemedicine has doubled year-over-year to 61% versus 28%, and half of consumers suggest they would consider a virtual behavioral therapist, Wieland tells investors in a research note. Even the 65 and over population is warming up to telemedicine, says the analyst. He reiterates an Overweight rating on Teladoc (TDOC). Wieland also believes Evolent Health (EVH) and Cerner (CERN) are well positioned for this trend.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:54
01/22/19
01/22
07:54
01/22/19
07:54
Periodicals
Amazon launches direct sales of merchandise in Brazil, Reuters reports »

Amazon has launched…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

STAA

STAAR Surgical

$35.10

0.59 (1.71%)

07:53
01/22/19
01/22
07:53
01/22/19
07:53
Recommendations
STAAR Surgical analyst commentary  »

Canaccord strongly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPC

Tutor Perini

$18.33

0.5 (2.80%)

07:53
01/22/19
01/22
07:53
01/22/19
07:53
Downgrade
Tutor Perini rating change  »

Tutor Perini downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$213.94

2.23 (1.05%)

07:52
01/22/19
01/22
07:52
01/22/19
07:52
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

BX

Blackstone

$32.91

0.28 (0.86%)

07:51
01/22/19
01/22
07:51
01/22/19
07:51
Periodicals
Blackstone CEO doesn't think U.S. on verge of recession, CNBC reports »

Blackstone Chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 11

    Feb

RDS.A

Royal Dutch Shell

$61.07

0.89 (1.48%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Downgrade
Royal Dutch Shell rating change  »

Royal Dutch Shell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMAC

DiaMedica Therapeutics

$3.50

-0.16 (-4.37%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Hot Stocks
DiaMedica Therapeutics announces publication of paper on KLK1, AIS »

DiaMedica Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$116.97

2.32 (2.02%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Alexion analyst commentary  »

Credit Suisse sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 04

    Feb

  • 18

    Feb

SMTX

SMTC Corp.

$5.60

0.12 (2.19%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Conference/Events
SMTC Corp. management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TIF

Tiffany

$89.85

4.6 (5.40%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HTHT

Huazhu Group

$34.94

1.94 (5.88%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
Huazhu Group initiated  »

Huazhu Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHG

GreenTree Hospitality

$12.97

0.18 (1.41%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
GreenTree Hospitality initiated  »

GreenTree Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.10

-0.135 (-2.58%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Conference/Events
TherapeuticsMD management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

ORTX

Orchard Therapeutics

$13.00

0.2 (1.56%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Hot Stocks
Orchard Therapeutics announces OTL-300 data published »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$62.51

1.99 (3.29%)

07:47
01/22/19
01/22
07:47
01/22/19
07:47
Hot Stocks
Jacobs Engineering awarded $93M contract for California WaterFix program »

Jacobs has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 19

    Feb

STT

State Street

$71.19

0.07 (0.10%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Recommendations
State Street analyst commentary  »

State Street price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

, TK

Teekay Corp.

$3.74

0.28 (8.09%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Teekay Offshore Partners, Teekay Corp. rating change  »

Teekay Offshore Partners…

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

TK

Teekay Corp.

$3.74

0.28 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZK

Bank OZK

$32.07

4.47 (16.20%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Bank OZK analyst commentary  »

Bank OZK price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$333.74

3.69 (1.12%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

TGTX

TG Therapeutics

$4.51

0.095 (2.15%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Hot Stocks
TG Therapeutics announces breakthrough therapy designation for umbralisib »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXP

Lexington Realty

$9.01

0.01 (0.11%)

07:44
01/22/19
01/22
07:44
01/22/19
07:44
Upgrade
Lexington Realty rating change  »

Lexington Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$6.83

-0.19 (-2.71%)

07:43
01/22/19
01/22
07:43
01/22/19
07:43
Hot Stocks
Cytokinetics announces FDA feedback for potential reldesemtiv program »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$22.94

0.99 (4.51%)

, FISV

Fiserv

$77.83

3.23 (4.33%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Downgrade
First Data, Fiserv rating change  »

First Data downgraded to…

FDC

First Data

$22.94

0.99 (4.51%)

FISV

Fiserv

$77.83

3.23 (4.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

SAIC

SAIC

$66.03

0.38 (0.58%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Conference/Events
SAIC management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

PSEC

Prospect Capital

$6.74

0.04 (0.60%)

07:41
01/22/19
01/22
07:41
01/22/19
07:41
Downgrade
Prospect Capital rating change  »

Prospect Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.